[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022012000A - Inhibidores de c5a para el tratamiento de infeccion por coronavirus. - Google Patents

Inhibidores de c5a para el tratamiento de infeccion por coronavirus.

Info

Publication number
MX2022012000A
MX2022012000A MX2022012000A MX2022012000A MX2022012000A MX 2022012000 A MX2022012000 A MX 2022012000A MX 2022012000 A MX2022012000 A MX 2022012000A MX 2022012000 A MX2022012000 A MX 2022012000A MX 2022012000 A MX2022012000 A MX 2022012000A
Authority
MX
Mexico
Prior art keywords
corona virus
virus infection
inhibitors
treatment
inhibitor
Prior art date
Application number
MX2022012000A
Other languages
English (en)
Inventor
Renfeng Guo
Niels C Riedemann
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of MX2022012000A publication Critical patent/MX2022012000A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un inhibidor de la actividad de C5a para su uso en el tratamiento de una afección médica causada por o asociada con una infección por un coronavirus. La invención también se refiere al uso de un inhibidor de la actividad de C5a en la reducción de una respuesta inflamatoria en un sujeto que padece una infección por un coronavirus. La invención se refiere además a un inhibidor de la actividad de C5a para su uso en la mejora de la función de órganos, en particular la función pulmonar y/o la función hepática, en un sujeto que padece una infección por un coronavirus.
MX2022012000A 2020-03-27 2020-03-27 Inhibidores de c5a para el tratamiento de infeccion por coronavirus. MX2022012000A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/058878 WO2021190770A1 (en) 2020-03-27 2020-03-27 INHIBITORS OF C5A FOR THE TREATMENT OF CORONA VIRUS Infection

Publications (1)

Publication Number Publication Date
MX2022012000A true MX2022012000A (es) 2022-10-20

Family

ID=70165988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012000A MX2022012000A (es) 2020-03-27 2020-03-27 Inhibidores de c5a para el tratamiento de infeccion por coronavirus.

Country Status (11)

Country Link
US (1) US20230158060A1 (es)
EP (1) EP4126222A1 (es)
JP (1) JP7535591B2 (es)
KR (1) KR20220159983A (es)
CN (1) CN116390758A (es)
AU (1) AU2020438234A1 (es)
BR (1) BR112022019090A2 (es)
CA (1) CA3172421A1 (es)
IL (1) IL296036A (es)
MX (1) MX2022012000A (es)
WO (1) WO2021190770A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
MX2023008302A (es) 2021-01-13 2023-09-25 Visterra Inc Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
PT2860251T (pt) 2004-02-12 2018-06-07 Archemix Llc Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
US20110301098A1 (en) 2006-07-21 2011-12-08 Quax Paul H A Treatment for intimal hyperplasia and related conditions
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EA020874B1 (ru) 2008-12-22 2015-02-27 Кемосентрикс, Инк. АНТАГОНИСТЫ C5aR
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
US9126939B2 (en) 2010-06-24 2015-09-08 Pingchen Fan C5AR antagonists
EP3119802B1 (en) 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
EP3194596A1 (en) 2014-09-16 2017-07-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
US20180142010A1 (en) 2015-06-26 2018-05-24 Alexion Pharmaceuticals, Inc. Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
AU2018286754A1 (en) * 2017-06-23 2019-12-19 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑

Also Published As

Publication number Publication date
US20230158060A1 (en) 2023-05-25
WO2021190770A1 (en) 2021-09-30
CN116390758A (zh) 2023-07-04
JP2023518884A (ja) 2023-05-08
EP4126222A1 (en) 2023-02-08
BR112022019090A2 (pt) 2022-11-08
AU2020438234A1 (en) 2022-09-29
JP7535591B2 (ja) 2024-08-16
IL296036A (en) 2022-10-01
KR20220159983A (ko) 2022-12-05
CA3172421A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MX2022002465A (es) Inhibidores de kras g12d.
MX337081B (es) Anticuerpo anti-nr10 y su uso.
EA201791747A1 (ru) 3-алкил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
MX2022012000A (es) Inhibidores de c5a para el tratamiento de infeccion por coronavirus.
MA34002B1 (fr) Thérapie antivirale
TR201901114T4 (tr) Özgün immünomodülatör ve anti inflamatuvar bileşikler.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2012093258A3 (en) Irf5- related treatment and screening
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
NZ785829A (en) Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease
NZ736807A (en) Gata-3 inhibitors for use in the treatment of th2-driven asthma
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2020012800A (es) Cannabinoides y usos de los mismos.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
MX2022014931A (es) Métodos de evaluacion del riesgo de desarrollar una respuesta severa a la infección por coronavirus.
CL2023001836A1 (es) Tratamiento de glomerulopatía c3 usando un inhibidor de c5a
PH12021551070A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MX2021015961A (es) Moleculas novedosas.
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
EA202190151A1 (ru) Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях
MX2020006605A (es) Polisulfato de pentosano y medicamento que contiene polisulfato de pentosano.
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof